Thailand’s pharmaceutical market is expected to experience consistent growth, fueled by robust local production and strong government backing, even amidst economic challenges. By 2034, generic drugs are anticipated to account for 50% of the market.
Key View
- We anticipate steady growth in Thailand’s pharmaceutical market, even amid the country’s broader economic slowdown.
- The government’s focus on local production will create opportunities for domestic drugmakers, while regulatory challenges may impact market entry for foreign drugmakers.
- By 2034, the generic market segment will account for around 50% of Thailand’s pharmaceutical market.
We anticipate steady growth in Thailand’s pharmaceutical market, even amid the broader economic slowdown. According to our Country Risk team, Thailand’s real GDP growth decelerated slightly from 3.2% year-on-year in Q4 2024 to 3.1% in Q1 2025. Despite this moderated economic expansion, in June 2025, Thailand’s House of Representatives approved the fiscal year 2026 budget, allocating THB265bn (USD8.1bn) to the National Health Security Office (NHSO). This allocation underscores the government’s commitment to bolstering national healthcare and ensuring widespread access to medical services.
The NHSO will use the budget to expand the National Essential Medicines List to include advanced treatments and launch public health campaigns such as ‘Healthy Thais, Free from Non-Communicable Diseases’, aimed at reducing chronic disease burden. The presence of robust funds is expected to underpin the pharmaceutical sector growth. We forecast Thailand’s pharmaceutical sales will reach THB214bn (USD6.0bn) in 2024 and THB275bn (USD8.3bn) by 2029, reflecting a five-year CAGR of 5.2% in local currency terms and 6.4% in US dollar terms.
Thailand’s pharmaceutical sector is facing a stable outlook despite ongoing economic constraints and regulatory challenges. With the country’s expanding healthcare needs and a growing demand for innovative therapies, the industry remains resilient. This stability is bolstered by the government’s initiatives to enhance local manufacturing capabilities and foster partnerships with international pharmaceutical companies, ensuring a steady pipeline of essential medications.
However, the sector is not without its hurdles. Economic uncertainties, including fluctuations in the global market and inflationary pressures, impose challenges on production costs and pricing strategies. Additionally, regulatory complexities can create barriers for new entrants and slow down the approval processes for new drugs. Nevertheless, the Thai government has taken steps to streamline these regulations, making it easier for companies to navigate the approval landscape.
In conclusion, while Thailand’s pharmaceutical industry contends with economic and regulatory headwinds, its strategic initiatives and growing market demand contribute to a positive outlook. Continued investment in innovation and a collaborative approach with international partners will further enhance the sector’s stability and growth in the coming years.
Read More
